Cwestiwn ysgrifenedig WQ88512
- Gofynnwyd gan
- Russell GeorgeCeidwadwyr
- I'w ateb gan
- Minister for Health and Social Services
- Cyflwynwyd
- Dyddiad ateb
- Atebwyd
- Amser i'w ateb
- 11 diwrnod
Cwestiwn
Mae'r cwestiwn a'r ateb yn Saesneg gan nad oes fersiwn Gymraeg ar gael.
What steps is the Welsh Government taking to support the Welsh Health Specialised Services Committee in securing the expansion of CAR-T treatment centres for patients across Wales?
Ateb
Atebwyd gan Minister for Health and Social Services
I recognise the importance of access to Advanced Therapeutic Medicinal Products (ATMPs) such as Chimeric Antigen Receptor T-cell (CAR-T) therapy. The Welsh Health Specialised Services Committee is responsible for commissioning this service on behalf of health boards in Wales.
The commissioning policies include equitable access and can be found at:
Specialised Services Policy Position: PP185
whssc.nhs.wales/commissioning/whssc-policies/cancer/chimeric-antigen-receptor-t-cell-car-t-therapy-policy-position-statement-pp185-april-2023/
Specialised Services Service Specification: CP176
whssc.nhs.wales/commissioning/whssc-policies/all-policy-documents/chimeric-antigen-receptor-t-cell-car-t-therapy-gilead-axicabtagene-ciloleucel-yescarta-service-specification-cp175-march-2019/
Specialised Services Service Specification: CP175
whssc.nhs.wales/commissioning/whssc-policies/all-policy-documents/chimeric-antigen-receptor-t-cell-car-t-therapy-novartis-tisagenlecleucel-kymriah-service-specification-cp176-march-2019/
The criteria for a unit to deliver CAR-T is described in these policies. There are no intentions at the present time to commission additional centres in Wales.